Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 21CNS 20Gastrointestinal 16Breast 14Genitourinary 11Gynecologic 9Thoracic 8Sarcoma 7Lymphoid 6Head & Neck 6Tumor-Agnostic 3Plasma cell 3Myeloid 3Other hematologic neoplasm 2Other solid neoplasm 1Classical hematology 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
poly ICLC × Tumor-Agnostic × Clear all
NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Seqker Biosciences, Inc.

Phase 1/2 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT01734564 2017-04-11

Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors

Clinica Universidad de Navarra, Universidad de Navarra

Phase 2 Completed
15 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡